Growth Metrics

Fennec Pharmaceuticals (FENC) Liabilities and Shareholders Equity (2016 - 2025)

Fennec Pharmaceuticals filings provide 16 years of Liabilities and Shareholders Equity readings, the most recent being $70.6 million for Q4 2025.

  • On a quarterly basis, Liabilities and Shareholders Equity rose 56.97% to $70.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was $211.1 million, a 10.64% decrease, with the full-year FY2025 number at $70.6 million, up 56.97% from a year prior.
  • Liabilities and Shareholders Equity hit $70.6 million in Q4 2025 for Fennec Pharmaceuticals, up from $49.3 million in the prior quarter.
  • In the past five years, Liabilities and Shareholders Equity ranged from a high of $70.6 million in Q4 2025 to a low of $15.6 million in Q2 2022.
  • Median Liabilities and Shareholders Equity over the past 5 years was $28.0 million (2021), compared with a mean of $36.6 million.
  • Biggest five-year swings in Liabilities and Shareholders Equity: plummeted 44.63% in 2022 and later skyrocketed 224.95% in 2024.
  • Fennec Pharmaceuticals' Liabilities and Shareholders Equity stood at $22.4 million in 2021, then increased by 20.19% to $26.9 million in 2022, then dropped by 0.28% to $26.9 million in 2023, then skyrocketed by 67.31% to $44.9 million in 2024, then soared by 56.97% to $70.6 million in 2025.
  • The last three reported values for Liabilities and Shareholders Equity were $70.6 million (Q4 2025), $49.3 million (Q3 2025), and $44.9 million (Q2 2025) per Business Quant data.